BREAKING
Earnings Summary: Zymeworks (ZYME) Q4 FY25 net loss widens 9 hours ago Earnings Summary: A snapshot of Smith+Nephew’s (SNN) Q4 2025 report 10 hours ago Earnings Summary: Norwegian Cruise Line (NCLH) Q4 FY25 revenue rises 6% 10 hours ago Earnings Summary: Highlights of Calumet’s (CLMT) Q4 2025 earnings report 3 days ago Zoom Communications Q4 2025 Earnings Results 4 days ago Agilent Q1 Revenue Rises 7%, Net Income Declines 4 days ago Synopsys Q1 2026 Earnings Results 4 days ago Key highlights from J.M. Smucker’s (SJM) Q3 2026 earnings results 4 days ago Hormel Foods (HRL) Q1 2026 Earnings: Key financials and quarterly highlights 4 days ago Key metrics from Lowe’s (LOW) Q4 2025 earnings results 5 days ago Earnings Summary: Zymeworks (ZYME) Q4 FY25 net loss widens 9 hours ago Earnings Summary: A snapshot of Smith+Nephew’s (SNN) Q4 2025 report 10 hours ago Earnings Summary: Norwegian Cruise Line (NCLH) Q4 FY25 revenue rises 6% 10 hours ago Earnings Summary: Highlights of Calumet’s (CLMT) Q4 2025 earnings report 3 days ago Zoom Communications Q4 2025 Earnings Results 4 days ago Agilent Q1 Revenue Rises 7%, Net Income Declines 4 days ago Synopsys Q1 2026 Earnings Results 4 days ago Key highlights from J.M. Smucker’s (SJM) Q3 2026 earnings results 4 days ago Hormel Foods (HRL) Q1 2026 Earnings: Key financials and quarterly highlights 4 days ago Key metrics from Lowe’s (LOW) Q4 2025 earnings results 5 days ago
JNJ

Johnson & Johnson

$JNJ NYSE Mar 3, 2026 DMH FY 2026

Investor Toolbox

Listen to Call

Watch or listen to the earnings call recording.

Open Webcast

Read Transcript

Transcript not yet available.

View Infographic

Visual summary of key financial data.

View Infographic

Earnings History

View past quarters and earnings trends.

View History

JNJ Coverage

Event Johnson & Johnson (JNJ) Early study results from Johnson & Johnson show promising antitumor activity with combination of pasritamig and docetaxel in advanced prostate cancer Feb 26, 2026 Event Johnson & Johnson (JNJ) Johnson & Johnson seeks FDA approval of IMAAVY® (nipocalimab-aahu) as the first-ever FDA-approved treatment for warm autoimmune hemolytic anemia (wAIHA) Feb 24, 2026 Event Johnson & Johnson (JNJ) TREMFYA® (guselkumab) long-term data show sustained clinical and endoscopic remission in ulcerative colitis through 3 years Feb 21, 2026 Transcript Johnson & Johnson (JNJ) Q4 2025 Earnings Call Transcript Jan 26, 2026 Transcript Johnson & Johnson (JNJ) Q2 2025 Earnings Call Transcript Jan 22, 2026 Transcript Johnson & Johnson (JNJ) Q3 2025 Earnings Call Transcript Jan 22, 2026 News Infographic: How Johnson & Johnson (JNJ) performed in Q4 2025 Jan 21, 2026 Research Johnson & Johnson: Healthcare Outlook Jan 20, 2026